drugset / Trial / NCT05753267
Fenofibrate in Ulcerative Colitis
Phase 2/3
Completed
60 enrolled
Tanta University
Hend El-Said Abo Mansour, Faculty of Pharmacy, Menoufia University · collabMonir Hussein Bahgat, Faculty of Medicine, Mansura University · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent.
Timeline
- Start
- 2023-02-28
- Primary completion
- 2025-09-20
- Completion
- 2025-09-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fenofibrate | Small molecule | 160 mg | — |
| Comparator | Mesalamine | Small molecule | 1 g | — |